Numinus Wellness Inc. NUMI NUMIFa mental health companies to advance innovative treatments and evidence-based psychedelics-backed therapies, announced that its research department Numinus Life Scienceshas developed one Psilocybin tea bag for use in clinical research and “when appropriate regulatory approvals are granted, eventual treatment of clients in psychedelic-assisted therapy.”
“The Numinus team developed the Psilocybe teabag with scientific precision,” he said Sharan Sidhu, Numinus VP, Scientific Research, Innovation & Laboratory Operations. “Our world-class team and resources allow us to control the entire production process, from growth to manufacture of the finished product, to deliver a fully standardized product.”
What’s in the tea bag?
The research behind the tea bag included the development of processes and procedures to deliver 25 mg per dose and the use of Numinus’ validated Psilocybe cubensis strains.
“The teabag is being evaluated in a Phase 1 study with practitioners receiving experiential training in psilocybin-assisted therapy with the aim of being used in research by Numinus, including trial partnerships at Cedar Clinical Research, the division of management clinical trials by Numinus.” according to a company press release.
That product has been submitted Health Canada Inclusion on the psilocybin supplier list for the Federal Special Access Program, through which healthcare providers can apply to offer psilocybin-assisted therapy to patients with a proven need, alongside other psychedelics-assisted therapies.
“Numinus recognizes that solid therapeutic products, such as whole mushrooms or pills, may be unattractive or difficult to use for certain populations, such as: dr Paul ThielkingChief Science Officer of Numinus.
“This new product is part of our commitment to increasing access to psychedelics-assisted therapies for those in need while helping…
